RU2761342C2 - Доставка терапевтических агентов в цнс - Google Patents

Доставка терапевтических агентов в цнс Download PDF

Info

Publication number
RU2761342C2
RU2761342C2 RU2017125281A RU2017125281A RU2761342C2 RU 2761342 C2 RU2761342 C2 RU 2761342C2 RU 2017125281 A RU2017125281 A RU 2017125281A RU 2017125281 A RU2017125281 A RU 2017125281A RU 2761342 C2 RU2761342 C2 RU 2761342C2
Authority
RU
Russia
Prior art keywords
composition
enzyme
lysosomal
storage disease
activity
Prior art date
Application number
RU2017125281A
Other languages
English (en)
Russian (ru)
Other versions
RU2017125281A3 (https=
RU2017125281A (ru
Inventor
Периклс КАЛИАС
Цзинь ПАН
Джен ПАУВЕЛЛ
Лоуренс ЧАРНАС
Томас Макколи
Тереса Леах РАЙТ
Ричард ПФАЙФЕР
Захра ШАХРОКХ
Original Assignee
Шир Хьюман Дженетик Терапис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45352777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2761342(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Хьюман Дженетик Терапис, Инк. filed Critical Шир Хьюман Дженетик Терапис, Инк.
Publication of RU2017125281A publication Critical patent/RU2017125281A/ru
Publication of RU2017125281A3 publication Critical patent/RU2017125281A3/ru
Application granted granted Critical
Publication of RU2761342C2 publication Critical patent/RU2761342C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
RU2017125281A 2010-06-25 2011-06-25 Доставка терапевтических агентов в цнс RU2761342C2 (ru)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US61/358,857 2010-06-25
US36078610P 2010-07-01 2010-07-01
US61/360,786 2010-07-01
US38786210P 2010-09-29 2010-09-29
US61/387,862 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US61/435,710 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US61/442,115 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US61/476,210 2011-04-15
US201161495268P 2011-06-09 2011-06-09
US61/495,268 2011-06-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012154831A Division RU2626514C2 (ru) 2010-06-25 2011-06-25 Доставка к цнс лечебных агентов

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021134682A Division RU2021134682A (ru) 2010-07-01 2021-11-26 Доставка терапевтических агентов в цнс

Publications (3)

Publication Number Publication Date
RU2017125281A RU2017125281A (ru) 2019-01-31
RU2017125281A3 RU2017125281A3 (https=) 2020-11-09
RU2761342C2 true RU2761342C2 (ru) 2021-12-07

Family

ID=45352777

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017125281A RU2761342C2 (ru) 2010-06-25 2011-06-25 Доставка терапевтических агентов в цнс

Country Status (24)

Country Link
US (17) US9814764B2 (https=)
JP (22) JP6250616B2 (https=)
CN (4) CN105664142A (https=)
AR (6) AR082025A1 (https=)
BR (1) BR112012033214B1 (https=)
CA (1) CA3171308A1 (https=)
CL (7) CL2012003655A1 (https=)
DK (3) DK3626258T3 (https=)
ES (3) ES2858726T3 (https=)
HK (1) HK1214149A1 (https=)
HR (3) HRP20211520T1 (https=)
HU (6) HUE046409T2 (https=)
LT (3) LT3626257T (https=)
MX (1) MX354776B (https=)
NZ (2) NZ702800A (https=)
PE (8) PE20130578A1 (https=)
PL (1) PL2588130T3 (https=)
PT (6) PT3626257T (https=)
RS (3) RS62620B1 (https=)
RU (1) RU2761342C2 (https=)
SI (3) SI3103469T1 (https=)
SM (1) SMT201600385B (https=)
TW (9) TWI602573B (https=)
UA (3) UA129740C2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
RS62620B1 (sr) 2010-06-25 2021-12-31 Shire Human Genetic Therapies Metode i kompozicije za isporuku cns akrilsulfataze a
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
NZ605874A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
NZ605873A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
EP2793933B1 (en) 2011-12-23 2019-04-17 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN105377039A (zh) * 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3292206B8 (en) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
WO2017116066A1 (en) 2015-12-30 2017-07-06 Green Cross Corporation Methods and compositions for treating hunter syndrome
EP4275751A3 (en) * 2016-02-24 2023-12-27 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
EP3760220B1 (en) * 2018-02-28 2025-02-19 Seikagaku Corporation A package comprising lyophilized chondroitinase abc and method for manufacturing the same
EP4417257A3 (en) 2018-02-28 2024-09-11 Seikagaku Corporation Pharmaceutical composition, package and method for producing the same
CN108534695A (zh) * 2018-05-04 2018-09-14 无锡恩特卫自动化检测设备有限公司 一种基于机器视觉系统的瓶塞漏酒检测方法及装置
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
WO2020004368A1 (ja) 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
JP7253770B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
PE20231931A1 (es) 2020-10-14 2023-12-01 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas
CN113283465B (zh) * 2021-04-02 2022-04-29 电子科技大学 一种弥散张量成像数据分析方法及装置
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
CN115116623A (zh) * 2022-06-28 2022-09-27 深圳市儿童医院 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端
IL326880A (en) * 2023-09-07 2026-04-01 Juvena Therapeutics Inc IGF2 fusion protein formulations and their medical uses
WO2025075929A1 (en) * 2023-10-02 2025-04-10 Neurona Therapeutics Inc. Methods of treating seizure activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089462A2 (en) * 2004-03-18 2005-09-29 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006054309A2 (en) * 2004-11-22 2006-05-26 Mediwound Ltd. Debriding composition from bromelain
US20060177433A1 (en) * 2002-04-25 2006-08-10 Treco Douglas A Treatment of alpha-galactosidase a deficiency
US20090017005A1 (en) * 2003-08-29 2009-01-15 Biomarion Pharmaceutical Inc. Delivery of Therapeutic Compounds to the Brain and Other Tissues

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
PT682524E (pt) * 1993-02-02 2002-03-28 Xoma Technology Ltd Composicoes farmaceuticas que contem a proteina bactericida indutora da permeabilidade e um agente tensioactivo
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
ES2185117T3 (es) 1997-08-22 2003-04-16 Seikagaku Kogyo Co Ltd Agente terapeutico para disco intervertebral herniado.
DK1137762T3 (da) 1998-12-07 2009-02-02 Genzyme Corp Behandling af Pompes sygdom
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
ATE384736T1 (de) 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US20030040479A1 (en) 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
WO2003032913A2 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003068159A2 (en) 2002-02-11 2003-08-21 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
AU2003299471A1 (en) 2002-05-07 2004-05-13 Kai Kroll Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
CA2487815A1 (en) 2002-05-29 2003-12-11 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
EP1426069A1 (en) 2002-12-02 2004-06-09 Diana Evelyn Miller Drug delivery system
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
PT2441467E (pt) 2003-01-31 2015-10-12 Sinai School Medicine Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
AU2004208962B2 (en) 2003-02-10 2010-07-15 To-Bbb Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CA2525236C (en) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
CA2556245A1 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
CN1922313B (zh) 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
UA11577U (en) 2004-04-21 2006-01-16 Academician A P Romodanov Inst Device for intrathecal drug administration into spinal canal
RU2006144851A (ru) * 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
ATE451472T1 (de) * 2004-08-11 2009-12-15 Basf Se Zeit-temperatur-indikator auf enzymbasis
WO2006121199A1 (ja) * 2005-05-11 2006-11-16 Oxygenix Co., Ltd. 脂質小胞体組成物
CN101541172A (zh) 2005-06-08 2009-09-23 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
DK1988823T3 (en) 2006-02-09 2018-12-03 Genzyme Corp SLOW INTRAVENTRICULAR ADMINISTRATION
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
ES2928096T3 (es) 2006-04-04 2022-11-15 Takeda Pharmaceuticals Co Un proceso para la concentración de un polipéptido
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US20080076120A1 (en) 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
WO2008109677A2 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
EP2174661B1 (en) 2007-06-29 2012-12-19 National University Corporation Nagoya University Agent for improving neuropathic pain
WO2009017005A1 (ja) 2007-07-27 2009-02-05 Sharp Kabushiki Kaisha 移動局装置、基地局装置、通信システム及びプログラム
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US8470771B2 (en) * 2007-11-14 2013-06-25 Institute Of Microbiology, Chinese Academy Of Sciences Method and medicament for inhibiting the infection of influenza virus
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CN105274072A (zh) 2008-01-18 2016-01-27 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
EP2588132A4 (en) 2010-06-25 2014-10-15 Shire Human Genetic Therapies METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
CN103179980B (zh) * 2010-06-25 2016-09-28 夏尔人类遗传性治疗公司 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物
NZ605874A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
NZ605873A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
CA2805449A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
RS62620B1 (sr) 2010-06-25 2021-12-31 Shire Human Genetic Therapies Metode i kompozicije za isporuku cns akrilsulfataze a
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US10722559B2 (en) 2014-08-11 2020-07-28 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
WO2016025523A1 (en) 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
WO2016065319A1 (en) 2014-10-24 2016-04-28 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
US9673835B1 (en) 2015-12-04 2017-06-06 Taiwan Semiconductor Manufacturing Co., Ltd. Pipelined SAR with TDC converter

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177433A1 (en) * 2002-04-25 2006-08-10 Treco Douglas A Treatment of alpha-galactosidase a deficiency
US20090017005A1 (en) * 2003-08-29 2009-01-15 Biomarion Pharmaceutical Inc. Delivery of Therapeutic Compounds to the Brain and Other Tissues
WO2005089462A2 (en) * 2004-03-18 2005-09-29 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2006054309A2 (en) * 2004-11-22 2006-05-26 Mediwound Ltd. Debriding composition from bromelain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE W. C. et al., Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy, The FASEB Journal, August, 2007,vol. 21 no. 10, рр. 2520-2527. Published online before print April 2, 2007, doi:10.1096/fj.06-6169com. *
WATSON G. et al., Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice, Gene Ther. 2006 Jun;13(11):917-25. *

Also Published As

Publication number Publication date
CL2012003654A1 (es) 2013-06-14
JP2018002734A (ja) 2018-01-11
US11471516B2 (en) 2022-10-18
HUE056884T2 (hu) 2022-03-28
JP2016040335A (ja) 2016-03-24
TW201815411A (zh) 2018-05-01
RU2017125281A3 (https=) 2020-11-09
UA125060C2 (uk) 2022-01-05
JP2021181489A (ja) 2021-11-25
US20180085438A1 (en) 2018-03-29
US12161702B2 (en) 2024-12-10
CN105664142A (zh) 2016-06-15
US12409210B2 (en) 2025-09-09
TW201825111A (zh) 2018-07-16
JP2023099216A (ja) 2023-07-11
JP2019031575A (ja) 2019-02-28
JP2021167340A (ja) 2021-10-21
JP6898909B2 (ja) 2021-07-07
HUE046856T2 (hu) 2020-03-30
LT3626257T (lt) 2021-12-10
UA125743C2 (uk) 2022-06-01
HK1218719A1 (zh) 2017-03-10
JP2023052868A (ja) 2023-04-12
JP7087175B2 (ja) 2022-06-20
PT2593131T (pt) 2019-10-30
UA129740C2 (uk) 2025-07-23
US20230026836A1 (en) 2023-01-26
US20250121040A1 (en) 2025-04-17
JP6466538B2 (ja) 2019-02-06
JP6250616B2 (ja) 2017-12-20
PT2588130T (pt) 2016-11-25
US20250161417A1 (en) 2025-05-22
PL2588130T3 (pl) 2017-09-29
SI3626257T1 (sl) 2021-12-31
HUE055963T2 (hu) 2022-01-28
JP2022024176A (ja) 2022-02-08
PE20130589A1 (es) 2013-05-19
ES2895655T3 (es) 2022-02-22
JP2018002735A (ja) 2018-01-11
CA3171308A1 (en) 2011-12-29
TWI698252B (zh) 2020-07-11
US20250375506A1 (en) 2025-12-11
US10456454B2 (en) 2019-10-29
RU2017125281A (ru) 2019-01-31
AR081681A1 (es) 2012-10-10
JP2021167341A (ja) 2021-10-21
JP2019006826A (ja) 2019-01-17
PT3103469T (pt) 2021-03-04
BR112012033214B1 (pt) 2020-11-03
JP7448507B2 (ja) 2024-03-12
MX2013000321A (es) 2013-04-03
JP7359827B2 (ja) 2023-10-11
HUE031036T2 (en) 2017-06-28
RS61683B1 (sr) 2021-05-31
JP2019038853A (ja) 2019-03-14
HUE046409T2 (hu) 2020-02-28
MX354776B (es) 2018-03-20
CL2017002488A1 (es) 2017-12-15
TW202112391A (zh) 2021-04-01
CL2012003656A1 (es) 2013-07-19
AR081679A1 (es) 2012-10-10
HRP20211520T1 (hr) 2021-12-24
RU2018113327A3 (https=) 2021-07-21
SMT201600385B (it) 2017-03-08
HRP20210298T1 (hr) 2021-04-16
JP6522072B2 (ja) 2019-05-29
US20200046810A1 (en) 2020-02-13
RU2018137304A3 (https=) 2022-02-22
TWI602573B (zh) 2017-10-21
US9814764B2 (en) 2017-11-14
RU2018113327A (ru) 2019-03-01
ES2858726T3 (es) 2021-09-30
TW201701899A (zh) 2017-01-16
US20170042978A1 (en) 2017-02-16
JP2020079297A (ja) 2020-05-28
PE20130579A1 (es) 2013-05-19
SI3626258T1 (sl) 2021-11-30
US11065307B2 (en) 2021-07-20
TW202506172A (zh) 2025-02-16
LT3103469T (lt) 2021-03-25
US20230165942A1 (en) 2023-06-01
AR082025A1 (es) 2012-11-07
JP7543459B2 (ja) 2024-09-02
JP6522073B2 (ja) 2019-05-29
TW202337489A (zh) 2023-10-01
TWI876260B (zh) 2025-03-11
DK3626257T3 (da) 2021-11-08
HUE052944T2 (hu) 2021-05-28
US20180071212A1 (en) 2018-03-15
HK1214149A1 (zh) 2016-07-22
CN105233277A (zh) 2016-01-13
JP2023062114A (ja) 2023-05-02
RS62620B1 (sr) 2021-12-31
US12121569B2 (en) 2024-10-22
CL2012003657A1 (es) 2013-04-19
US20130295077A1 (en) 2013-11-07
PT3626257T (pt) 2021-11-12
US11260112B2 (en) 2022-03-01
US20200405825A1 (en) 2020-12-31
US20140271598A1 (en) 2014-09-18
JP2020079298A (ja) 2020-05-28
PE20130578A1 (es) 2013-05-19
US20170042977A1 (en) 2017-02-16
ES2896060T3 (es) 2022-02-23
CN106139133B (zh) 2020-12-04
BR112012033214A2 (pt) 2017-05-23
US20200113981A1 (en) 2020-04-16
CL2020000468A1 (es) 2020-09-04
AR081680A1 (es) 2012-10-10
PT3626258T (pt) 2021-10-19
JP2016040337A (ja) 2016-03-24
PE20130637A1 (es) 2013-06-13
US10646554B2 (en) 2020-05-12
RS62520B1 (sr) 2021-11-30
JP2017214434A (ja) 2017-12-07
JP7591476B2 (ja) 2024-11-28
TWI790444B (zh) 2023-01-21
US12168041B2 (en) 2024-12-17
US20190183984A1 (en) 2019-06-20
PE20180130A1 (es) 2018-01-18
CL2012003655A1 (es) 2013-04-19
DK3626258T3 (da) 2021-09-20
US20220133862A1 (en) 2022-05-05
JP6285409B2 (ja) 2018-02-28
PE20130648A1 (es) 2013-07-03
US20160158324A1 (en) 2016-06-09
JP6797876B2 (ja) 2020-12-09
NZ702800A (en) 2017-03-31
AR081678A1 (es) 2012-10-10
JP2016094451A (ja) 2016-05-26
JP2020079244A (ja) 2020-05-28
TWI669128B (zh) 2019-08-21
TW201206465A (en) 2012-02-16
CN105233277B (zh) 2019-01-01
AR081677A1 (es) 2012-10-10
LT3626258T (lt) 2021-12-10
JP2016037504A (ja) 2016-03-22
CN106139133A (zh) 2016-11-23
TW201212936A (en) 2012-04-01
TWI609694B (zh) 2018-01-01
JP6938456B2 (ja) 2021-09-22
DK3103469T3 (en) 2021-02-22
HRP20211660T1 (hr) 2022-02-04
JP2024097029A (ja) 2024-07-17
CN104857504A (zh) 2015-08-26
NZ702803A (en) 2017-05-26
PE20170938A1 (es) 2017-07-13
PT2585104T (pt) 2019-10-30
JP6346162B2 (ja) 2018-06-20
RU2018137304A (ru) 2019-03-21
US9220677B2 (en) 2015-12-29
JP2016041755A (ja) 2016-03-31
SI3103469T1 (sl) 2021-04-30
PE20180801A1 (es) 2018-05-09
TW201726161A (zh) 2017-08-01
US11065308B2 (en) 2021-07-20
CL2016003159A1 (es) 2017-05-12

Similar Documents

Publication Publication Date Title
RU2761342C2 (ru) Доставка терапевтических агентов в цнс
US9833618B2 (en) Methods and compositions for treating a disease condition in a subject
KR102005752B1 (ko) 국소지방 제거용 주사제 조성물
KR101859486B1 (ko) 설하용 덱스메데토미딘 조성물과 그의 사용 방법
NZ605865A (en) Cns delivery of therapeutic agents
ES2953560T3 (es) Procedimiento para el tratamiento o reducción de paniculopatía fibrosclerótica edematosa
SI2613798T2 (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
KR102683501B1 (ko) 지방분해용 주사제 조성물
EP2589382A1 (en) Pharmaceutical composition comprising levocarnitine and dobesilate
Montiel et al. Modulation of the autophagy‐lysosomal pathway and endoplasmic reticulum stress by ketone bodies in experimental models of stroke
CR20250293A (es) Formulaciones de enzima hialuronidasa para la administración de alto volumen
CN101610760B (zh) （s）-心得乐在制备治疗恶病质的药物中的用途
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
CN101426490B (zh) 包含α-酮戊二酸/盐的组合物及其用于调节肌肉性能的用途
KR101883903B1 (ko) 저장성 지방 분해 조성물 및 그의 제조 방법
RU2021134682A (ru) Доставка терапевтических агентов в цнс
CN104906501A (zh) 治疗银屑病的中药组分组合物
RU2791085C1 (ru) Способ купирования болевых синдромов
RU2348417C1 (ru) Способ коррекции нейроэндокринного и иммунного состояния организма (варианты)
US20230144882A1 (en) Use of adenosine deaminase and adenosinedeaminase modifier in preparation of medicamentfor wound repair in patient with diabetes
KR20180071977A (ko) 저장성 지방 분해 조성물 및 그의 제조 방법
KR20180071978A (ko) 저장성 지방 분해 조성물 및 그의 제조 방법
US20170340647A1 (en) Preservative-free Treprostinil Formulations and Methods and Devices for Use with Same
Karamanakos et al. Disulfiram neuropathy: two cases of distal axonopathy
GREGORIADIS stability or increase the volume of aqueous spaces (3